Topic:

M&A

Latest Headlines

Latest Headlines

Hospira may be just the tip of the iceberg for deal-hungry Pfizer

Pfizer may have agreed on Thursday to pick up injectable drugmaker Hospira for $17 billion, but don't expect it to stop its dealmaking there, analysts say.

Thermo Fisher buys into bioproduction with $300M for Advanced Scientifics

Research and lab-focused Thermo Fisher Scientific has acquired bioprocessing provider Advanced Scientifics (ASI) for $300 million in cash. The deal adds into the revenue mix ASI's global business providing biopharma preparation, processing, storage and transportation systems and equipment.

Pfizer's still a likely buyer after its $17B 'hors d'oeuvre'

After signing up to acquire Hospira for $17 billion, Pfizer is just getting started, analysts say, pointing to Pfizer's failed quest for AstraZeneca as evidence that the drugmaker is looking for some transformational M&A.

S&N touts acquisition track record, says appetite remains 'undiminished'

Smith & Nephew is working toward having two-thirds of its revenue coming from higher growth areas. Acquisitions are core to that goal--in fact, during the fourth quarter any organic growth was wiped out by the impact from currency exchange and the only revenue growth came from its surgical devices acquisitions, which grew by 12%.

Strong earnings suggest Allergan sold too cheap, analyst says

Allergan's fourth-quarter and full-year financials are out, and the way Bernstein analyst Ronny Gal sees it, based on the company's performance, it "should have asked for more money" from buyer Actavis.

Cost-cutting, check. Now, it's on to dealmaking, Teva chief says

Teva is ready to make some deals now. It's a mantra that's seen quite a bit of play since CEO Erez Vigodman took up the reins at the generics giant early last year. But now, after a year of focusing on cutting costs and debt, and turning things around at the struggling drugmaker, he really means it.

AstraZeneca continues its respiratory land grab with $600M-plus Actavis deal

AstraZeneca CEO Pascal Soriot has said he wants to dominate in the respiratory field. Actavis CEO Brent Saunders has no such ambitions. Now, the two have struck a deal.

UPDATED: Pfizer beefs up on biosimilars with $15B Hospira deal

Pfizer CEO Ian Read is dipping into the pharma giant's big reserve of cash to gobble up Hospira, one of the pioneers in the move to develop biosimilars of blockbuster biologics.

UPDATED: Hospira to merge with Pfizer for $16B amid device overhaul

Hospira is merging with Pfizer for about $16 billion as the company attempts to revive its long-beleaguered device business and cash in on a growing sterile injectables and biosimilars market.

Pfizer grabs Hospira's biosims, generic injectables in $15B takeover

Pfizer has snapped up Hospira, an injectables specialist, for $90 per share, or some $15 billion, plus debt assumption.